

# PRODUCT INFORMATION



## galacto-Dapagliflozin

Item No. 15952

CAS Registry No.: 1408245-02-2

Formal Name: (1S)-1,5-anhydro-1-C-[4-chloro-3-[[4-ethoxyphenyl)methyl]phenyl]-D-galactitol

MF:  $C_{21}H_{25}ClO_6$

FW: 408.9


Purity:  $\geq 95\%$

UV/Vis.:  $\lambda_{\max}$ : 224 nm

Supplied as: A crystalline solid

Storage:  $-20^{\circ}\text{C}$

Stability: As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly



### Laboratory Procedures

galacto-Dapagliflozin is supplied as a crystalline solid. A stock solution may be made by dissolving the galacto-dapagliflozin in the solvent of choice. galacto-Dapagliflozin is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of galacto-dapagliflozin in ethanol and DMSO is approximately 30 mg/ml and approximately 50 mg/ml in DMF.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of galacto-dapagliflozin can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of galacto-dapagliflozin in PBS, pH 7.2, is approximately 0.25 mg/ml. We do not recommend storing the aqueous solution for more than one day.

### Description

Renal glucose transport is mediated by sodium-glucose cotransporters (SGLT) 1 and 2.<sup>1</sup> In humans, SGLT2 is responsible for the majority of glucose reabsorption in the kidney.<sup>1</sup> galacto-Dapagliflozin is a potent inhibitor of human SGLT2 that is 1,000-fold less potent at human SGLT1 ( $K_i$  values are 2 and 25,000 nM, respectively).<sup>2</sup> It also dissociates from hSGLT2 more slowly than from hSGLT1 (half-time off rates are 19 and 0.9 seconds, respectively).<sup>2</sup>

### References

1. Hummel, C.S., Lu, C., Loo, D.D.F., *et al.* Glucose transport by human renal  $\text{Na}^+$ /D-glucose cotransporters SGLT1 and SGLT2. *Am. J. Physiol. Cell Physiol.* **300**, C14-C21 (2011).
2. Hummel, C.S., Lu, C., Liu, J., *et al.* Structural selectivity of human SGLT inhibitors. *Am. J. Physiol. Cell Physiol.* **302**(2), C373-C382 (2012).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/27/2016

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM